Jazz Pharma's 841% Price Increase On A Sleep Drug Could Attract Attention From Capitol Hill

Published: Nov 03, 2016

What happened

Shares of Jazz Pharmaceuticals PLC, an Irish-based biopharmaceutical company primarily focused on the development of therapies to treat sleep disorders, fell 10% in October, based on data from S&P Global Market Intelligence.

Although it was a pretty quiet month in terms of press releases for Jazz, the culprit appears to be pricing concerns for its lead drug, Xyrem.

So what

One campaign issue that's gained a lot of press since September 2015 is prescription-drug reform.

Back to news